GlassScriptPhysician profile
Ann V Collie
NPI 1518096767
$3,605.94
in general payments reported to CMS, 2019-2025
30 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $346 · 2021: $524 · 2022: $704 · 2023: $829 · 2024: $651 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $508.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $430.78 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.56 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $203.31 | 2020-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $176.80 | 2019-2024 | |
| Abbvie INC. | $173.11 | 2019-2025 | Synthroid |
| Corcept Therapeutics | $159.95 | 2019-2024 | Korlym |
| Insulet Corporation | $150.62 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $150.38 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $147.42 | 2020-2023 | Freestyle Libre 3, Freestyle Libre |
| Amgen INC. | $145.69 | 2019-2023 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $138.61 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.25 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $119.32 | 2019-2023 | Farxiga |
| Dexcom, INC. | $105.35 | 2019-2023 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $99.78 | 2021-2024 | Unithroid |
| Amarin Pharma, INC. | $83.43 | 2020-2022 | |
| Cequr Corporation | $59.42 | 2023-2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $52.38 | 2019-2020 | |
| Grt US Holding, INC. | $38.04 | 2022 | |
| Companion Medical, INC. | $37.16 | 2019 | |
| Ibsa Pharma INC. | $31.68 | 2020-2023 | Tirosint, Licart |
| Neurocrine Biosciences, INC. | $27.05 | 2024 | |
| Ascendis Pharma Endocrinology INC | $21.65 | 2023 | |
| Alexion Pharmaceuticals, INC. | $16.88 | 2022 | |
| Medtronic, INC. | $16.61 | 2022 | |
| Lifescan, INC. | $15.52 | 2021 | |
| Glaxosmithkline, LLC. | $15.25 | 2025 | Shingrix, Arexvy |
| Horizon Therapeutics Plc | $13.34 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Collie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.